As the leading AI-based microbiome drug development company in China, Xbiome Co., Ltd. is dedicated to gut microbiome using AI techniques, and committed to the gut health of human being with medical treatments and precise and personalized management.
The gut is the largest microbial ecosystem in the human body. It hosts about 100 trillion microbes – 500 – 1000 unique species, and contains 150-fold more genes than the human genome, which influence the human health systematically. Studies show that more than 50 human diseases are associated with dysbiosis of gut microbiota.
Unlike the traditional paradigm of drug discovery, Xbiome's approach innovatively combines microbial technologies, artificial intelligence, bioinformatics analysis and gut microbiome technologies into a unique drug development platform, which substantially speeds up and improves the success rate of new drug development.
Company Details
- Employees
- 51
- Founded
- -
- Address
- Cambridge, Massachusetts, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- xbiome.com
- HQ
- Cambridge, Massachusetts
Xbiome Questions
Xbiome's website is xbiome.com
Xbiome's LinkedIn profile is https://www.linkedin.com/company/xbiome
Xbiome has
51 employees.
View email and phone details for 51
employees at Xbiome.
Xbiome's industry is
Biotechnology Research
Xbiome's top competitors are
Receptor.ai,
Amply Discovery,
Elegen,
Zap Surgical Systems, Inc.,
Insight Data Science,
Foundation Medicine,
Xellar Biosystems,
Arkeabio™,
Manifold Bio,
Xilis.
Xbiome's categories are Biotechnology Research
Xbiome's founding year is 2017
